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Abstract
Cyanoprokaryotes are distributed worldwide and they produce various bioactive 
compounds, including cyanotoxins. The major route of human exposure to cyano-
toxins is the oral intake by using contaminated drinking water, by incidental intake of 
contaminated water during recreational and professional activities, and by consuming 
contaminated food or dietary supplements prepared from cyanobacteria. The pro-
longed chronic exposure to low concentrations of cyanotoxins provokes cell damage and 
may increase the risk for cancer development. Due to the variety of cyanotoxin chemical 
structures, different mechanisms of their toxic effects are known. At the same time, 
some of the natural compounds produced by cyanoprokaryotes have anticancer poten-
tial and are promising sources for the development of novel drugs. This chapter is dedi-
cated to the target mechanisms behind the effects of the widely distributed cyanotoxins 
with an impact on human health, microcystins, nodularins, and cylindrospermopsin.
Keywords: cyanotoxins, microcystins, nodularins, cylindrospermopsin,  
toxicity mechanisms
1. Introduction
Cyanoprokaryotes are Gram-negative photosynthetic algae considered to have 
arisen approximately 3.5 billion years ago [1]. In nature, they are found as single cell 
species or as colonies rapidly growing in fresh water, all types of aquatic ecosystems, 
and terrestrial habitats. Cyanobacteria are photosynthetic organisms, and as such, they 
are considered primary first-level consumers in the food chains in water ecosystems. 
Blue-green algae play an important role in carbon and nitrogen balance in the biosphere 
[2]. They produce a high number of bioactive molecules, and certain species produce 
cyanotoxins that contribute as defense mechanisms against different ambient stress 
factors [3]. The growth of cyanobacteria at high blooming densities increases in expan-
sion and frequency following anthropogenic activities and climatic change, globaliza-
tion, and increasing commodity exchanges [4]. This, in turn, raises morbidity and 
death rates of wild and domestic animals [5, 6] and brings some risk to human health.
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More than 90 microcystin isoforms, that are cyclic peptide cyanotoxins, have 
been described. The microcystin-leucine arginine (MC-LR) is known as the most 
toxic and the most abundant variant of microcystins [7]. Several authors have 
reported that MC-LR has been considered as the most widely spread microcystin in 
Portuguese waters [8]. However, Rodrigues et al. report similar results for micro-
cystin MC-RR (a MC variant with the amino acid arginine in positions 2 and 4) 
[9]. MC-RR is the major toxin variant found in the rivers, lakes, and reservoirs in 
China [10] reaching concentrations of up to 93.5% in the cells of cyanoprokaryotes 
[11], thus associated with the contamination produced by intensive use of water 
sources and fast economic development [12]. In Bulgaria, a country rich in water 
reservoirs and natural water bodies, many cases of cyanoprokaryote blooms have 
been reported. Surveys conducted for a period of 15 years (2000–2015) in 120 
Bulgarian water basins have recorded cyanobacteria blooms in 14 water bodies and 
have identified 16 cyanotoxins (microcystins LR, LA, RR, YR, nodularins, and 
saxitoxins) [13].
Cyanotoxins have various chemical structures; thus, their toxic effects are due to 
different mechanisms. Cyanotoxins are classified into three major groups according 
to their chemical structure: alkaloids (cylindrospermopsin, saxitoxin, lyngbya-
toxin-a, and aplysiatoxin,), cyclic peptides (microcystins, MCs, and nodularins—
NODs), and lipopolysaccharides [14]. Poisoning of humans with cyanotoxins is 
possible through various pathways, mainly by the consumption of contaminated 
food (vegetables, fish, seafood, and livestock), as well by bathing and recreational 
activities with contaminated water [15]. Different studies have reported high 
accumulation of cylindrospermopsin (CYN) in fish (up to 2.7 ng/g) [16], in mussels 
(up to 2.52 mg/g) [17], and in lettuce (up to 8.029 μg/kg) [18].
Along with the reports about the toxicity of cyanobacteria metabolites, there are 
studies describing their anticancer properties, hence, viewing them from a new per-
spective as novel potential sources for anticancer drug development [19]. However, 
to identify possible drug targets, the science about the mechanisms of the toxicity 
needs to be extracted out of the numerous scientific reports and review studies on 
cyanobacteria blooms, case studies and investigations on the effects of cyanotoxins 
described by different authors.
This review addresses the target mechanisms behind the effects of widely dis-
tributed groups of cyanotoxins with an impact on human health, the cyclic peptides 
microcystins and nodularins, and the alkaloid cylindrospermopsin.
Data collection was performed through keyword research, namely cyanotoxins, 
microcystins, nodularins, cylindrospermopsin, cyanotoxins/microcystins/nodular-
ins/cylindrospermopsin molecular mechanisms/carcinogenicity/anticancer poten-
tial/clinical toxicology/poisoning incidence/clinical toxicology. ScienceDirect and 
PubMed databases were screened for the above-mentioned key words. More than 
100 papers were examined and bibliography includes references dating back to 1878.
2. Water blooms, human and animal health
A great number of studies about cyanotoxins discuss their toxicity from dif-
ferent points of view. Clinical intoxication cases and epidemiological studies on 
reported cases of exposure to cyanobacteria and their toxins are described [20]. 
There are reports on acute poisonings of animals and humans due to exposure to 
cyanotoxins [21, 22]. Chronic intake of contaminated water; aerosolization, includ-
ing respirable bioaerosols; consumption of contaminated seaborne food [23]; or 
even intake of dietary supplements containing blue-green algae are investigated and 
reported [24].
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Observational studies on the correlation between clinical symptoms and contact 
with blooming water have been recorded throughout the centuries. The earliest 
report on such poisoning dates back 1000 years ago in China when green-colored 
river water consumption caused mortality in General Zhu Ge-Ling’s troops, accord-
ing to data reviewed on the website of National Toxicology Program, Department of 
Health and Human Services of USA [25]. Later in 1878, cyanotoxin poisoning was 
suspected in Australia [26]. In several US states, gastroenteritis has been suspected to 
be related to water blooms [27]. In China, primary liver cancer has been attributed to 
cyanotoxin-contaminated drinking water [28]. In a profound recent review, Svircev 
et al. [20] identified 42 publications that describe 33 cases of cyanotoxin poison-
ing in 11 countries—Australia, Brazil, Canada, China, Namibia, Portugal, Serbia, 
Sri Lanka, Sweden, the UK, and the USA for the period between 1960 and 2016. 
Although there is no definitive general conclusion in the epidemiological literature, 
it identifies a possible link between microcystins and cancer and other human health 
issues [20]. Wood [21] presents an informative table summarizing reports about 
acute animal and human poisonings attributed to exposure to cyanotoxins since 
1800; there is an estimate of the number of affected animals and individuals in 
incidents of mortality and morbidity from 1900 onwards. The author identified 115 
human incidents of cyanotoxin intoxications reported until the year 2010, mostly 
seen in the United States and Canada, followed by Europe [21]. Taking into account 
the great variety of cyanobacteria and their overall environmental distribution in 
fresh and brackish waters and the fact that more than 90 different types of cyanotox-
ins are produced by the blue-green algae, the various routes of cyanotoxin poisoning, 
as well as the variety of clinical manifestations encountered, we may expect that the 
above numbers are quite underestimated. In Varna region, Bulgaria, no evidences to 
related cases of acute poisoning to cyanotoxins have been documented according to 
local database [118]. Furthermore, it is not always easy to derive information about 
countries classified by Woods as “the rest of world,” especially when information 
dated back centuries ago. Sometimes, data are published in the gray literature 
and in the local language; data available are not supported by adequate scientific 
information. Often clinical evidences of inflammatory response or allergic reac-
tions are misleading for being common symptoms for other types of intoxications 
as well; such clinical cases remain in the group of idiopathic intoxications and are 
not reported as cases of cyanoprokaryota poisonings. Cyanobacteria content in the 
total mass of phytoplankton in different waters and sampling periods may vary up 
to 100%. Usually, in algae blooms, one species predominates and it releases various 
cytotoxins to the water. Some toxins have been detected even after the end of algae 
blooms, when cyanoprokaryota species are already in negligible concentrations [13].
Few reports describe correlation between defined clinical symptoms and/or 
laboratory findings and a reported contact and/or consumption of contaminated 
water. The most severe human intoxication with cyanotoxins occurred in Brazil 
in 1996, where 100 of 131 dialysis patients developed acute hepatic failure due to 
cyanotoxin contamination of the dialysis water applied. The death of 52 of them 
has been confirmed to be due to the presence on cyanotoxins in treatment water 
provided from a local water treatment plant [29, 30]. Another incidence, again in 
Brazil, associates 2000 cases of gastroenteritis and 88 deaths with blooms [31]. 
Microcystis aeruginosa–contaminated water caused pneumonia in two patients 
in Staffordshire, England [32]. In Australia, 140 children and 10 adults have 
experienced liver and kidney problems. Cylindrospermopsin is reportedly the 
etiological agent [33]. Giannuzzi et al. [34] report a case from Argentina in 2007. 
Microcystin-LR is detected in water samples, where the patient has been immersed 
before experiencing acute clinical symptoms. In addition, laboratory examination 
identified increase of markers for liver injury (ALT, AST, and GGT).
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3. Cyclic peptides—toxicity and biotransformations
The cyclic pentapeptide nodularins and cyclic heptapeptide microcystins are the 
most widespread cyanotoxins in water blooms. MCs are produced by different cya-
nobacterial species (Microcystis, Oscillatoria, Aphanocapsa, Cyanobium, Arthrospira, 
Limnothrix, Phormidium, Hapalosiphon, Anabaenopsis, Nostoc, and Synechocystis). 
It is known that nodularins are produced only by cyanobacteria from the genus 
Nodularia (Nodularia spumigena) [35]. Various investigations reveal approx. 100 
known variants of MCs up-to-date with the most toxic and widely distributed 
MC being MC-LR [36]. The maximum concentration of MC-LR is up to 1 μg/L in 
drinking water. This is the conditional guideline value adopted by the World Health 
Organization (WHO). The value is based on tolerated daily intake (TDI) 0.04 μg/
kg body weight [37].
Most of the microcystins have hydrophilic structure; thus, their cell uptake 
should be facilitated by transporting systems, such as the organic anion trans-
porting polypeptides (OATPs). Many OATPs are expressed in a tissue-specific 
way, whereas others are expressed ubiquitously [38]. A selective uptake of MCs 
by the cells, depending on the organ type and on the expression of different 
OATPs, is established in intestines, liver, muscle, and brain cells of three differ-
ent catfish species [39]; the highest contents are found in liver, gonads, stomach, 
heart, and kidneys in Wistar rats [40]. The fact that MC accumulation is primar-
ily in the liver is explained by the amount of OATPs present in this organ, which 
is why MCs are considered as hepatotoxins. More specifically, the MC-LR has 
been determined as a substrate for OATP1A2, OATP1B1, and OATP1B3. MCs are 
established to require active transport for human cell uptake, and the high expres-
sion of these OATP1B1 and OATP1B3 transporters in the liver accounts for their 
selective liver toxicity [41, 42]. Researches reveal that OATP1B1 and OATP1B3 
expression is detected in cell lines originating from liver, colon, and pancreatic 
tumors [43], as well as in hepatocellular carcinoma [44]. These results account for 
microcystin toxicity to be examined mainly in hepatocytes in vivo and in cultured 
hepatic cells in vitro.
The liver of the fish species O. bonariensis, collected from a shallow lake in 
Argentina, contained 10 times higher MC-RR levels than the muscles, reports a 
study [45]. Another study, on mice, elucidates that 9% of the MC-LR toxin fraction 
is filtrated in the kidneys and eliminated through urine, thus making kidneys a 
possible object for MC-LR toxicity as well [46]. Pflugmacher et al. [47] determine 
that the first stage in the detoxification of MCs is the formation of a glutathione 
conjugate of MC (MC-LR-GSH) in hepatocytes, identified earlier in mice and in 
rat livers [48]. MC-LR-GSH is then further metabolized to a cysteine conjugate 
(MC-LR-Cys) for excretion via urine [49], via feces as well, as free MCs or their 
metabolites [50].
Chronic exposure to sublethal doses of MCs could lead to induction of oxida-
tive stress, necrotic cell death, and liver neoplasia in animals [51] and a possible 
reason for that could be the depletion of GSH cell stores. A study demonstrates 
the bioaccumulation of microcystin-LR (MC-LR) in mammals [52]. A pig experi-
mental model has been used because of its liver, kidney, and gastrointestinal tract 
function similarities to humans, as well as similarities to humans’ metabolic rates 
[53]. Although MC-LR is not found in the serum of treated animals, free MC-LR 
is detected in the large intestine and kidneys, in liver as well, where the MC-LR-
glutathione conjugate is in high quantity, approximately 1.1% of the applied 
MC-LR dose. The chemical structures of unabsorbed MCs are not modified, or 
few changes occur. MCs are transported to the intestine and further are excreted 
by feces. The other route is absorption and subsequent conjugation in the liver 
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and rapid excretion of this compound in the bile [54]. MC-LR and its derivatives 
(MC-LR-GSH and MC-LR-Cys) may also enter the enterohepatic circulation and, 
being reabsorbed into the blood stream, may reach the brain, heart, lungs, and even 
testicles [55].
Animal studies mark the possible MC-LR accumulation in human hepatic 
tissue exposed chronically to high doses of cyanotoxins as well. Present-day study 
analyses daily exposure to MCs and their effects on human health; authors identify 
the presence of MCs in anglers’ serum, most likely resulting from exposure to 
ingested MC from consumed fish [56]. Serum enzymes aspartate aminotransferase, 
alanine aminotransferase, lactate dehydrogenase, and alkaline phosphatase, which 
are biomarkers of hepatic function, are elevated, pointing to liver damage in the 
fishermen. The smaller ring structure of NODs is taken up by the liver cells more 
easily than MC-LR, thus probably resulting in stronger hepatocellular effects [57]. 
Another research provides evidence that MC-LR can be transported across the 
blood-brain barrier in humans [41].
3.1  Cyclic peptides—molecular toxicity mechanism in relation to carcinogenicity
Different mechanisms of cytotoxicity are observed among MC variants and 
nodularins in a range of in vitro cell culture studies on cell viability and the ability 
to cause apoptosis or necrosis in varying concentrations applied to different cell 
types. Fastner et al. [58] explicates that primary rat hepatocytes are less suscep-
tible to MC-RR (EC50 1500–4300 nM) compared to MC-LR (EC50 60–200 nM). 
Independently of the cell culture type (primary or transfected hepatocytes), 
MC-RR is always less cytotoxic than MC-LR [59]. Gacsi et al. [60] have studied the 
effects of MC-LR on cultured Chinese hamster ovary cells (CHO-K1) in order to 
detect cell viability and to determine if nonviable cells go through necrosis or apop-
tosis. The study demonstrates that low dose of MC-LR (<10 μM) after 24 h expo-
sure does not induce apoptosis in the cell line. The application of higher MC-LR 
concentrations (⩾20 μM) shows induced apoptosis in a concentration-dependent 
manner. The shrinkage of apoptotic cells is linked to the shortening and loss of 
actin filaments and microtubule depolymerization. No necrosis is observed over the 
concentration range tested. Piyathilaka et al. [61] evaluates the MC-LR cytotoxic 
and apoptotic effects on different human kidney cell lines—normal embryotic 
(HEK-293) and adenocarcinoma cell line (ACHN). The MTT and sulforhodamine 
B (SRB) cell viability assays establish that MC-LR is more cytotoxic to embryonic 
kidney cells compared to kidney adenocarcinoma cells after treatment with MC-LR 
for 24 h. In addition, morphological studies also reveal higher MC-LR toxicity to 
kidney cancer cells than to normal kidney cells. MC-LR does not promote cell divi-
sion of human kidney adenocarcinoma cells, indicating that it cannot be a promoter 
of kidney cancer [61].
NODs and MCs are among the most common natural cyanotoxins. Their toxic-
ity is mainly due to the ability to inhibit the eukaryotic protein serine/threonine 
phosphatase families 1 and 2A (PP1 and PP2A), which are essential for many signal 
transduction pathways of eukaryotic cells. This inhibition is linked to protein 
hyperphosphorylation, thus leading to modification of cytoskeleton and distur-
bances of many cellular processes: loss of cell-cell adhesion at the desmosomes [62], 
disruption of actin filaments [63], and altered cell signaling pathways, for example 
MAPKs signaling pathways that regulate cellular proliferation [55]. As potent 
inhibitors of protein serine/threonine phosphatase, MCs and NODs have a pro-
found effect on cell signaling leading to the affected cell’s death. Both MC-LR and 
NOD have inhibitory effect on protein phosphatases, independently that MC-LR 
binds covalently to them and NOD does not [64].
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Cell signaling pathways involving MAPKs regulate cellular proliferation through 
phosphorylation cascades. Several types of phosphatases including the protein 
serine/threonine phosphatases 2A regulate the Ras-Raf-MEK-ERK cascade (PP2A). 
The phosphatase PP2A inhibits these pathways by dephosphorylation. The acti-
vated (phosphorylated) forms of the transcription factor ERK1/2 are translocated 
to the cell nucleus, thus leading to the transcription of certain proto-oncogenes 
[65]. Junttila et al. [66] speculate that by inhibiting PP2A, MC-LR could deregulate 
the ERK1/2 pathway, thus promoting cell proliferation and tumorigenesis.
NODs and MCs also play a role as potential oxidants, which could induce reac-
tive oxygen species production, hence causing cell oxidative stress damages [67]. 
Many studies demonstrate that oxidative stress is involved in the liver cell toxicity 
due to MCs [68] and NODs [67]. Increased production of reactive oxygen spe-
cies (ROS) and lipid peroxides in mouse liver because of treatment with NODs is 
observed [69].
MCs may increase the production of ROS by depletion of GSH due to a high 
rate of conjugation [8, 67]. These observations are confirmed in zebrafish [70], 
where MC administration leads to lipid peroxidation and a change in the antioxi-
dant enzyme activity [71]. A study explicates MC-RR influence on gene expres-
sion of nuclear factor—erythroid 2 related factor 2 (Nrf2), a master regulator of 
inducible antioxidant responses, in human hepatocytes, causing mitochondria 
dysfunction [72]. The transcription factor Nrf2 has been identified as a key factor 
in the cell protection from oxidative stress and electrophilic insults [73, 74]. 
Many of Nrf2 target genes play essential role in maintaining cellular antioxidant 
responses and xenobiotic metabolism. Its constitutive activation may contribute 
to a malignant phenotype [75], and its elevated expression and activity have been 
observed in different cancer cells [76]. Nrf2 promotes the survival of tumor cells 
under a deleterious environment and elevates resistance to antitumor drugs [77]. 
These observations suggest that Nrf2 plays contrasting roles in different tumori-
genesis stages and is subject to MCs’ toxicity with predictable effect on further 
tumorigenesis.
Gan et al. have shown that MC-LR is able to enhance the stability of the Nrf2 
transcription factor in the cytoplasm and its translocation to the nucleus via 
binding to the cytosolic regulator protein Keap1. Knockdown of Nrf2 mediated by 
siRNA can inhibit cell proliferation and cell cycle progression induced by MC-LR 
[78]. Therefore, upregulation of Nrf2 induced by MC-LR in tumor cells favors liver 
cancer cell growth. This study gives additional information supporting Nrf2 role 
in cancer tumorigenesis [78], respectively, of MC-LR. Moreover, a higher level of 
Nrf2 in toxin-treated rat primary hepatocytes after 48 h has been observed [79]. It 
is assumed that inhibition of protein phosphatases by MCs may affect the activity of 
DNA-dependent protein kinase (DNA-PK), an enzyme with key role in the nonho-
mologous terminal binding of DNA loops in the G0-phase of the cell cycle observed 
in human lymphocytes [80].
Another important mechanism of genotoxicity is the impairment of DNA repair. 
Experimental animals exposed to sublethal low doses of MC have shown to develop 
tumorigenesis in coordination with the presence of dysfunctional p53 [81]. The 
increased formation of reactive oxygen species leads to oxidative DNA damage. A 
study shows that after 4 h of exposure to 0.01, 0.1, and 1 mg/mL of MC-LR DNA 
strand breaks were induced in dose dependent manner in human liver carcinoma 
cell line (HepG2 cells) [82]. Oxidized pyrimidines are repaired within a short time 
of exposure to MCs (8 h), while oxidized purines (mainly 8-hydroxyguanine) 
remain unrepaired in the DNA and accumulate [83] leading to GC-TA transversion 
mutations [84]. This statement has been verified in vivo with demonstrated eleva-
tion of 8-hydroxyguanine in male rat hepatocytes 24 h after treatment with 50 mg/
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kg body weight of MC-LR [85]. In primary cultured rat liver cells exposed to NOD, 
the highest level of 8-oxo-2′-deoxyguanosine adducts is observed after 3 h exposure 
and its level decreased to control cells’ levels after 24 h of exposure [85].
Many studies on MC-LR adverse effects establish its ability to change gene 
expression, and by these means contribute to a better understanding of MC-LR 
mechanisms linked to toxicity, genotoxicity, and carcinogenicity potential. Sueoka 
et al. [86] give the first evidence that MC-LR modulates the expression of tumor 
suppressor genes and oncogenes. They demonstrate that primary rat liver cells 
exposed to MC-LR (1 mM) for 6 h remarkably elevated the tumor necrosis factor α 
(TNF-α) expression, which could play the role of an endogenous tumor promoter 
[87]. The same study shows upregulation of early-response genes from the jun 
and fos gene families, proto-oncogenes, which are involved in gene regulation in 
response to different stimuli such as growth factors, cytokines, and viral and bacte-
rial infections (Table 1).
In summary, one pathway of MC genotoxic activity is mediated by induction 
of ROS generation, thus leading to DNA strand breaks and at the same time sig-
nificantly decreasing DNA repair system activity. The impairment of DNA repair 
together with DNA damage is an important factor involved in tumorigenesis. 
Chronic exposure to low concentrations of these cyanotoxins may increase the risk 
for carcinogenesis due to their potential long-term adverse effects (carcinogenic and 
genotoxic). For this reason, the International Agency for Research on Cancer clas-
sifies MC-LR as a possible human carcinogen [88]. Figure 1 summarizes possible 
mechanisms of MR-LR genotoxicity with contribution to carcinogenesis.
Experimental 
model
Time/dose of 
exposure/method of 
administration
Main findings Reference
Male Wistar rats Single intravenous 
administration of МС-LR 
extract; 80 μg/kg body 
weight
The maximum MC-LR content 
(2.9% of the injected dose) 
detected 2 h after injection. 
Highest concentration found in 
kidney (0.034–0.295 μg/g dry 
weight); concentration in liver 
(0.003–0.052 μg/g dry weight).
[40]
Fish species O. 
bonariensis collected 
in Los Padres Lake 
(Argentina)
Fish residing in 
intoxicated water (MC-
LR, -RR, -YR, and -LA 
total content in water: 
2.8 ± 5.6 μg L−1)
Total content of MCs in liver 
(33.6 ± 37.2 μg kg−1) is 10-fold 
higher than that in the fish muscles 
(3.9 ± 2.2 μg kg−1).
[45]
Pigs (breed, PIC 337) Oral administration of 
MC-LR in two treatment 
groups:
1. 0.04 μg MC-LR/
kg body weight for 
13 weeks
2. 2 μg toxin/kg body 
weight for 5 weeks
MC-LR not detected in serum; free 
MC-LR found in the large intestine 
(1.4 μg/kg dry weight) and kidney 
(1.9 μg/kg dry weight).
The higher dosed animals 
accumulated MC-LR-conjugate in 
liver (26.4 μg/kg dry weight).
[52]
129-Trp53tm1BrdN4 
mice (homozygous 
p53 knockout B6 
mice)
Intraperitoneal injection 
of MC-LR, 40 μg/kg body 
weight for 4, 24 h, and 4, 
14, and 28 days
Increased proliferative response in 
liver after 28 days exposure time 
as detected by increased nuclear 
Ki-67 immunoreactivity and 
phosphohistone H3 expression.
[81]
Table 1. 
Microcystins in animal studies.
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3.2. Cyclic peptides—potential sources of anticancer drugs
Essential for candidate molecules to be developed into useful anticancer thera-
peutics is their cancer selectivity. It is known that specific types of cancer can be 
targeted by redox-based therapies when cancer cells are assailable by increased 
ROS production induced by exogenous agents [89]. Thus, microcystin analogues 
are assumed to be selective anticancer drugs for certain types of cancer cells, 
specifically for those that express OATP, without causing significant toxicity to 
normal cells because of the differences of redox status between normal and cancer 
cells [90]. The development of OATP-targeting compounds based on the chemical 
structure of MC-LR, with unique physicochemical properties such as high water 
solubility, resistance to chemical hydrolysis or oxidation at near-neutral pH, and 
stability in pH shifts, appears to be a feasible and promising option in this direction 
[91]. There are studies focused on developing analogues of microcystin cyanotoxins 
for efficiently targeting the OATP-expressing metastatic cancers, which are resis-
tant to conventional chemotherapy treatment [90] and many known cyanotoxins 
have been studied for their anticancer properties in human cell lines.
Currently, neither optimal nor targeted therapy has been developed for pancreatic 
cancer [92]. Overexpression of OATPs in pancreatic cancer offers an opportunity to 
develop effective novel cancer-targeted agents. A study demonstrates that MC-LR tar-
geting OATP1B1 and OATP 1B3 can cause inhibition of proliferation of pancreatic can-
cer cells in a dose-response mode [92]. Study findings point that antiproliferative and 
pro-apoptotic effects are proportionally related to the expression of these transporters, 
thus suggesting an essential role for OATP expression in the process of MC-LR–induced 
cancer cell damage. Moreover, direct comparison of the inhibitory effect of MC-LR and 
the drug gemcitabine manifests a noticeable advantage of the toxin [92].
Monks et al. [93] have transfected cervical cancer cell line HeLa with the known 
OATP1B1 and OATP1B3 transporters seeking through appropriate in vitro models 
how MCs are uptaken into the cells and testing the activity of MCs against cells 
that express OATPs. Authors elucidate that transfected HeLa cells were 1000-fold 
more sensitive to MC-LR compared to the vector-transfected control cells, pointing 
that the expression of transporters imparts marked selectivity for MC cytotoxicity 
[93]. These observations suggest that MC cytotoxicity in OATP1B1- and OATP1B3-
expressing HeLa cells is linked to cell-specific inhibition of PP2A and not to protein 
phosphatase inhibition in general.
Figure 1. 
Mechanisms of microcystin genotoxicity.
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These findings endorse the anticancer potential of MCs and raise hopes that 
cyanotoxins may have a promising future in cancer therapy. Challenges of potential 
organ-specific MC toxicity remain to be resolved by proper chemical modifications 
in the process of drug modulation.
4.  Cylindrospermopsin—molecular mechanisms of toxicity and 
biotransformation
Humans are more susceptible to the exposure to cylindrospermopsin in compari-
son to other cyanotoxins because up to 90% of the total CYN is found outside the 
cyanobacterial cells [94]. Humpage et al. [95] recommend a maximum concentration 
of CYN in drinking water to be 1 μg/L based on tolerated daily intake, 0.03 μg/kg 
body weight.
CYN is generated by different freshwater cyanobacteria species, which are com-
mon worldwide, nowadays [96]. Many cyanotoxins are generally sequestered inside 
cyanobacteria until death, while cylindrospermopsin can be liberated in water 
during blooms [97].
CYN is a polycyclic uracil derivative containing guanidino and sulfate groups. 
The cyanobacterial toxin CYN is a tricyclic alkaloid that consists of a tricyclic 
guanidine moiety combined with hydroxymethyluracil. CYN has been recognized 
to induce cytotoxicity in vitro in human cell lines from liver and intestine [98]. The 
toxin primarily attacks the liver, but it is also a general cyanobacterial toxin that 
targets the spleen, kidney, heart, lungs, thymus, eyes, etc. [99].
The mechanisms of CYN toxicity and genotoxicity are not fully clarified. It 
is assumed that there are two types of toxic responses. It is established that CYN 
is more toxic in short-term (1–2 weeks) compared to long-term exposure in cell 
culture experiments [100]. Rapid toxicity is due to CYP450-generated metabolites 
[95]. The longer-term toxicity of CYN includes an irreversible inhibition of eukary-
otic protein synthesis in in vitro experiments [98].
Many studies explore the cytotoxic effect of cylindrospermopsin and they are 
summarized in Table 2. These studies vary in type of cell culture used, time of 
exposure, concentrations of the CYN, and even the type of cytotoxicity test used.
Most in vitro experiments demonstrate that the cytotoxic effect of cylindro-
spermopsin is observed after long-term exposure (24–72 h). Toxicity of CYN on 
primary and carcinoma cell line is compared: the primary rat hepatocyte cells are 
more sensitive to the toxic effect of CYN, compared to KB cell line [101].
Morphological studies are more informative than cytotoxicity studies as they 
identify the types of cell damage. By means of microscopy, in that respect, pleomor-
phic nuclei, nucleolar segregation with altered nuclei, depraved Golgi apparatus, 
and apoptosis in human endothelial cells (HUVEC) after exposure to 0.375 μg/mL, 
CYN is observed [15]. The same authors also report morphological changes (mito-
chondrial damage, lipid degeneration, and nucleated segmentation with altered 
nuclei) in Caco-2 cells after exposure to a higher concentration of CYN (2.5 μg/mL). 
Absorption of CYN in Caco-2 cells is very limited, which explains the result [105]. 
Authors report that after cells being exposed to concentration of CYN 1–10 μM for 
3, 10, and 24 h, the passage of CYN across the intestinal monolayer is about 2.5% 
after 3 h and increases slightly up to 20.5% after 24 h.
In search for possible mechanisms of CYN toxicity, it is observed that CYN 
significantly reduces GSH levels in rats’ primary hepatocytes; a decline in the syn-
thesis of GSH is the predominant mechanism, rather than an increased glutathione 
consumption [106], which could lead to increased oxidative stress. Other authors 
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observe different and contradictory effects of CYN on the activity of gamma-
glutamylcysteine synthetase (GCS)—the regulatory enzyme in GSH synthesis. In 
any case, reduction of GSH levels does not contribute significantly for the acute 
CYN toxicity in vivo as presumed, because no changes in the oxidative stress mark-
ers after exposure to CYN are evidenced [95].
The role of biotransformation of CYN is an important factor for understanding 
its toxic effect in cell lines, respectively, in various tissues. Scientific data show that 
toxicity and genotoxicity of CYN depend on cytochrome P450 (CYP)-mediated 
metabolism, as various CYP inhibitors can protect cells against toxicity, but it is not yet 
clear which isoforms are involved [95]. The higher activity of CYP450 in hepatocytes 
Experimental 
model
Method 
applied
Experimental 
conditions
Results Reference
Primary rat 
hepatocytes
MTT 
assay
0–10,000 ng/mL for 24, 
48, 72 h exposure
The LC50 is 40 ng/mL; 
toxic effects are observed 
after 72 h.
[101]
Primary mouse 
hepatocytes
MTT 
assay
1–5 μM/mL 1–5 μM CYN induces 
concentration-dependent 
cytotoxicity in 18 h.
[102]
Primary human 
granulosa cells
MTT 
assay
0–1 μg/mL for 2, 4, 6, 
24, 48, 72 h exposure
There is no effect when cells 
are exposed up to 1 μg/mL 
for short time (2–6 h). Cell 
viability is decreasing in a 
concentration-dependent 
way for longer time 
(24–72 h).
[103]
Hepatic cell 
lines: C3A and 
HepG2; colonic 
cell line: Caco-2
MTT 
assay
0.4–66 μM for 1, 2, 4, 6, 
24 h exposure
The IC50 is 1.5 μM for 
C3A and HepG2 for 24 h 
exposure.
The IC50 is 6.5 μM for 
Caco-2 for 25 h exposure.
[98]
CHO K1cells Annexin 
V-FITC 
assay
0.1–10 μM for 12, 18, 24, 
48 h exposure
Apoptosis is observed 
at low concentrations 
(1–2 μM) and short 
exposure (12 h).
Necrosis is observed at 
higher concentrations 
(5–10 μM) and following 
longer exposure (24 or 
48 h).
[60]
KB (human 
cervix 
carcinoma) 
cells
MTT 
assay
0–10,000 ng/mL for 24, 
48, 72 h exposure
The LC50 is 200 ng/mL; 
toxic effects are observed 
after 72 h
[101]
HeLa cells MTT 
assay
40, 20, 10, 5, 1, and 
0.1 mg DW (lyophilized 
cyanobacterial 
biomass)/mL 
(cultivation medium) 
for 24 h of exposure
The IC50 is 0.2 ± 0.06 mg 
of lyophilized biomass 
per milliliter of culture 
medium.
[104]
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide); KB (human cervix carcinoma) cells; C3A 
(human hepatocellular carcinoma); HepG2 (human liver hepatocellular carcinoma cell line); Caco-2 (human 
colorectal adenocarcinoma cell line); CHO-K1 (Chinese hamster ovary K1 cells); Annexin V-FITC (fluorescein 
isothiocyanate labeled annexin V); HeLa (human cervical epithelial adenocarcinoma).
Table 2. 
In vitro cytotoxicity studies performed with cylindrospermopsin.
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involved in bioactivation events is found to be important for CYN toxicity in liver 
cell cultures [107]. Many in vitro and in vivo studies on the toxic mechanisms of CYN 
prove that metabolites of the toxin produced by CYP450 are mainly responsible for its 
toxicity, including its genotoxicity. Thus, the activity of the cytochrome P450 enzyme 
system has been investigated [102], demonstrating that the inhibition of CYP450 
activity by proadifen or ketoconazole in mouse hepatocytes reduces the toxicity of 
CYN but does not alter its effect on protein synthesis. These observations may explain 
lower CYN toxicity in cell lines such as human cervix carcinoma (KB cells) [101], 
HeLa cell types [100], and CHO-K1 cells [108] compared to primary rat hepatocytes. 
Another study reveals that CYP1A1 and CYP1A2 are upregulated in human peripheral 
blood lymphocytes after CYN exposure [109].
Due to the simultaneous presence of different cyanobacterial toxins in aquatic 
environment, Hercog et al. [110] investigated the genotoxic potential of MC-LR 
and CYN mixtures, applied on HepG2 cells. Cells are treated with different doses 
of CYN, a single dose of MC-LR, and several combinations. A mixture of MC-LR 
and CYN provokes genotoxic damages, but to a lesser extent in case of strand 
breaks, compared to CYN itself. Data manifest that MC-LR provoke DNA strand 
breaks after short-term exposure, while CYN induces DNA damage after pro-
longed exposure in metabolically active cells [95, 111]. These data point that CYN 
exhibits higher genotoxic effects compared to MC-LR in the mixture of CYN and 
MC-LR. The same authors disclose mRNA expression levels of certain genes after 4 
and 24 h of exposition to CYN or to MC-LRs, or to a combination of both cyanotox-
ins. Changes in the expression levels of genes involved in the metabolism of xeno-
biotic, genes involved in immediate-early response/signaling, and genes involved in 
response to DNA damage, upon exposure to CYN/MC-LR mixture, are not different 
to those induced by CYN itself [110], indicating higher genotoxicity of CYN.
In summary, the main target of CYN toxic activity is the liver, and CYN metabo-
lism plays an important part for understanding the mechanisms of its toxicity. 
Therefore, the activity of CYP450 enzyme system is considered a key mechanism 
for CYN toxicity development in hepatocyte cultures, including genotoxicity. The 
higher sensitivity of liver cells exposed to CYN is due to bioactivation-dependent 
events, research indicates [105]. One of the CYN-known mechanisms is the irrevers-
ible inhibition of protein synthesis after long-term exposure [98]. Another mecha-
nism is via oxidative stress induced by inhibiting the regulatory enzyme in GSH 
synthesis [106]. CYN induces DNA damage after longer exposure in metabolically 
active cells [95].
4.1. Anticancer properties of cylindrospermopsin
Caco-2 cells and HepG2 are often used human cell lines for cyanotoxin effects 
research. A study showed that CYN is linked to a variable effect in HepG2 cell line. 
Cyanotoxin diminishes lipid peroxidation in cells that have not been previously 
induced by phenobarbital exposure for 12 h and elevates it in phenobarbital-
induced cells exposed to the highest CYN concentration (10 μg/L). Lipid peroxida-
tion increases in both cell types after 24 h exposure, only at 10 μg/L CYN [112], 
demonstrating that the toxicity of low concentrations of CYN (<10 μg/L) is limited 
in human hepatoma cells. HepG2 cells are more sensitive compared to intestinal 
cells, while Caco-2 cells are even less sensitive. The observation is associated with 
the limited CYN uptake in colon cells as described by several authors [105, 113].
Oral intake is the major route of human exposure to CYN, which makes intestine 
a target organ. Huguet et al. [114] examined the cellular and molecular mechanisms 
of cylindrospermopsin toxicity on differentiated cell line of human intestinal 
Caco-2 cells. This cellular monolayer provides in vitro model performing functional 
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and morphological characteristics similar to those of enterocytes. Results reveal 
that differentiated Caco-2 cells exposed for 24 h to a subtoxic cylindrospermopsin 
concentration overexpress the gene products linked to DNA damage repair, includ-
ing nucleosomal histone modifications [114]. Bain et al. examined the potential 
role of p53 tumor suppressor protein in CYN-induced gene expression in human 
hepatocellular carcinoma cell line [111]. Authors report that after 6 h of exposure to 
CYN, concentration-dependent increases in mRNA levels are observed for the p53 
target genes CDKN1A, MDM2, GADD45alpha (all involved in the response to DNA 
damage), and BAX (involved in the apoptosis), indicating an early activation of p53 
by CYN. The respective levels of mRNA for these genes remain elevated after 24 h. 
Data suggest that CYN can induce stress responses resulting in activation of the p53 
transcription factor [111] and subsequent upregulation of DNA repair processes 
and activation of apoptosis.
That being said, a 72 h exposure of HepG2 cell line to CYN provokes DNA 
double strand breaks, providing evidence that CYN can perform as a direct geno-
toxin [115].
Obviously, available scientific data indicate controversial roles of CYN 
and its toxicity. CYN can cause severe cell damages, and it has the potential to 
activate DNA repair processes, which, concerning concentration and time-of-
exposure–dependent activities, makes it another promising potential anticancer 
drug source.
5. Clinical toxicology and pharmacological aspects
Scientific paper analysis reveals some mechanisms linked to exposure to 
cyanotoxins and their effect on human health. Many episodes of severe poison-
ings have been registered after acute exposure, associated with adverse effects. 
Epidemiological studies reveal correlation between cyanotoxins and their toxic 
effects on human health [20].
Symptoms of poisoning by drinking water are much like those of gastrointes-
tinal disturbances caused by a number of pathogenic bacteria, thus hampering 
differentiation of poisoning with cyanotoxins. Data for chronic exposure to low 
cyanobacterial toxin levels are still not well investigated.
Concerning the chemical diversity of cyanotoxins, the pathobiochemical 
mechanisms for cyanotoxin-associated diseases are variable [116] and the mecha-
nism of toxicity is different. Thus, there is no universal antidote for treatment of 
cases of cyanobacteria intoxications. One treatment strategy is to apply chemo-
protectants, especially for treatment of microcystin intoxications. However, there 
is less research available on cylindrospermopsin-induced toxicity treatment [99]. 
Commonly discussed is the application of antioxidants with vitamin E having 
the strongest protective effect, as oxidative stress is one of the most common 
pathobiochemical mechanisms of cyanobacteria intoxications. In reference to 
available knowledge about cellular uptake of cyanotoxins, especially microcys-
tins, transport inhibitors are considered for potential administration in cases of 
cyanobacteria-related intoxications and in combination with other therapies. The 
antibiotic rifampin is reported as an example of such a drug approved for clinical 
use [117].
Due to nondefinitive manifestation of cyanotoxin poisoning, symptomatic 
treatment is applied, including oxygen application, aiming at respiratory distress 
amelioration, activated charcoal gastric lavage, forced diuresis for toxin elimina-
tion by glomerular filtration, alkalization, and hepatoprotective medication 
administration [118].
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6. Discussion
Cyanobacterial blooms have been registered worldwide for centuries, and a cor-
relation to associated human and animal illness has been suspected. Subsequently, 
it has been documented that blue-green algae produce various bioactive compounds 
with the common name cyanotoxins. Taking into account the wide variety of 
cyanobacteria, their effect on all aquatic ecosystems, and the various manifestation 
of cyanotoxin poisoning, it is essential to elucidate their toxicity mechanisms, as 
well as adequate treatment.
Most common and well-examined cyanotoxins are the ones of the microcystin 
family. Epidemiological studies do not provide definitive confirmation of linkage 
of acute or chronic exposure to cyanotoxins and human cancer development. Some 
animal studies demonstrate cyanotoxins’ carcinogenic potential. Intraperitoneal 
injection of MC-LR in sublethal dose causes neoplastic nodules in mouse liver [119]. 
MC-LR application causes liver cancer in dose-dependent manner in rat model where 
protein phosphatase type 1 and type 2A activities’ inhibition has been established 
[120]. Inhibition of serine/threonine phosphatase activity is a possible link between 
toxic and suspected carcinogenic potential of microcystins. Supporting evidences 
for this hypothesis, for example, are the findings that PP2A phosphatase inhibition 
by microcystins leads to disruption of MAPK signal transduction pathway [55]. This 
can be a possible explanation for increased proto-oncogene transcription observed 
[65] and promoted cell proliferation and tumorigenesis [66] in experiments with this 
kind of toxins. Considering research limitations of microcystin effects on humans, 
further investigations and evidence collection are needed to provide more robust 
correlation between cyanotoxin poisoning and cancer development.
CYN cancer potential has been less studied and not fully explained. It is assumed 
rather indirect. CYN metabolism and biotransformation with the participation 
of CYPs generate reactive metabolites and exhaust cellular glutathione. Thus, its 
toxicity and/or carcinogenic potential may be attributed to generated (geno)toxic 
metabolites and compromised antioxidant cellular defense.
Cellular penetration of MCs is mediated by tissue-specific OATPs. 
Overexpression of these transporters in certain cancer cells [92] provides an oppor-
tunity for the development of effective novel cancer-targeted agents. In support of 
this hypothesis, transfection of HeLa cancer cells with OATPs has been established 
to increase their susceptibility to MC treatment as compared to vector-transfected 
control cells [93]. More studies in this field are necessary to provide valuable data 
about MCs’ application as anticancer remedies.
7. Conclusions
Cyanobacteria are proved in various habitats, such as drinking water reservoirs 
and recreational waters, at the basis of food chains, and thus, with a substantial 
impact on ecosystems and human health. Centurial observations of a correlation 
between water blooms and health issues in animals and humans are extended in 
numerous epidemiological, in vivo and in vitro, studies. Various bioactive compounds 
under the common name cyanotoxins are established as the reason for blooming 
water toxicity. Some of the toxic molecular mechanisms for certain cyanotoxins are 
clarified. Their bioavailability, metabolism, and biotransformation are proved as well. 
A possible link between cyanotoxin exposure and cancer development has been sus-
pected and there is experimental research data in support of this hypothesis. Yet, cya-
nobacteria produce natural compounds with promising potential for the discovery of 
novel anticancer drugs. Improved alertness about cyanotoxin poisoning, its relation 
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to water blooms, poisoning symptoms, and specific treatment is needed in view of 
adequate human and animal health promotion and health care. Cyanobacteria have 
already been in the focus of food and pharmaceutical industry and cosmetics for a 
long time, incorporated in different preparations and food supplements. This requires 
raised awareness of the population and responsible institutions about the hazards of 
cyanotoxin contamination regarding food, water, and health remedies.
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